Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Feb 15;11(4):383–396. doi: 10.1159/000522424

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2022 by The Author(s). Published by S. Karger AG, Basel

This article is licensed under the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC). Usage and distribution for commercial purposes requires written permission. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

PMC Copyright notice

Fig. 2 — Kaplan-Meier curves for OS among all patients (a), PFS (b) among all patients, OS in the PSM cohort (c), and PFS in the PSM cohort (d). The median OS for the LEN-TACE group was 31.2 (26.4–34.3) months, and this for the LEN monotherapy group was 15.7 (13.1–19.4) months, respectively (p = 0.001, a). The median PFS for the LEN-TACE group was 12.2 (8.5–17.3) months, and this for the LEN monotherapy group was 6.7 (5.3–10.2) months, respectively (p = 0.025, b). The median OS for the LEN-TACE group was 31.2 (26.4–34.3) months, and that for the LEN monotherapy group was 13.9 (13.1–29.2) months, respectively (p = 0.002, c). The median PFS for the LEN-TACE group was 12.2 (8.5–17.3) months, and this for the LEN monotherapy group was 7.1 (5.3–12.8) months, respectively (p = 0.037, d). LEN, lenvatinib; TACE, transcatheter arterial chemoembolization; OS, overall survival; PFS, progression-free survival.